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The mucin MUC4 is a high molecular weight transmembrane glycoprotein. It consists of a mucin-type subunit (MUC4a) and a
transmembrane growth factor-like subunit (MUC4b). The mucin MUC4 is overexpressed in many epithelial malignancies including
ovarian cancer, suggesting a possible role in the pathogenesis of these cancers. In this study, we investigated the functional role of
MUC4 in the human ovarian cancer cell line SKOV3. The mucin MUC4 was ectopically expressed by stable transfection, and its
expression was examined by western blot and confocal microscopy analyses. The in vitro studies demonstrated an enhanced motility
of MUC4-expressing SKOV3 cells compared with the vector-transfected cells. The mucin MUC4 expression was associated with
apparent changes in actin organisation, leading to the formation of microspike, lammelopodia and filopodia-like cellular projections.
An enhanced protein expression and activation of HER2, a receptor tyrosine kinase, was also seen, although no significant change was
observed in HER-2 transcript levels in the MUC4-transfected SKOV3 cells. Reciprocal co-immunoprecipitation revealed an
interaction of MUC4 with HER2. Further, the MUC4-overexpressing SKOV3 cells exhibited an increase in the phosphorylation
of focal adhesion kinase (FAK), Akt and ERK, downstream effectors of HER2. Taken together, our findings demonstrate that MUC4
plays a role in ovarian cancer cell motility, in part, by altering actin arrangement and potentiating HER2 downstream signalling in
these cells.
British Journal of Cancer (2008) 99, 520–526. doi:10.1038/sj.bjc.6604517 www.bjcancer.com
& 2008 Cancer Research UK
Keywords: MUC4; ovarian cancer; HER2; motility
                                               
Ovarian cancer is a highly lethal disease. It often goes undiagnosed
until the last stage when it has already spread to distant sites. The
current therapeutic strategies for tackling this malignancy are still
inefficient and tumour recurrence of up to 70% is observed in
patients with advanced ovarian carcinoma even after treatment
(Auersperg et al, 2001, 2002; Jemal et al, 2007). The mortality from
ovarian cancer could be significantly lowered by developing new
strategies for the early diagnosis and treatment. A better under-
standing of the molecular mechanisms underlying its progression
and the aggressive phenotype is therefore an urgent requirement
for developing novel and effective therapeutic modalities for the
treatment of this deadly malignancy.
Mucins are large, heavily glycosylated proteins that provide
protection to the luminal epithelial surfaces under normal
physiological conditions (Moniaux et al, 2001; Hollingsworth and
Swanson, 2004). Alteration in the expression or glycosylation
pattern of mucins is often associated with the development of
cancer by influencing key cellular functions including growth,
differentiation, transformation, adhesion and invasiveness of
tumour cells and immune surveillance (Andrianifahanana et al,
2001; Hollingsworth and Swanson, 2004). The mucin MUC4 is a
transmembrane mucin that frequently displays an altered expres-
sion in many cancers (Carraway et al, 2001b; Hollingsworth and
Swanson, 2004; Andrianifahanana et al, 2006).
Previous studies from our laboratory have revealed an aberrant
expression of the MUC4 in more than 90% of ovarian tumours,
whereas a very low to no expression was detected in the normal
ovaries (Chauhan et al, 2006). An overexpression of MUC4 mRNA
has also been previously reported in ovarian cancer (Giuntoli et al,
1998; Lopez-Ferrer et al, 2001). The deduced full-length amino-
acid sequence of the MUC4 apoprotein shows the presence of a
leader peptide, a serine and threonine-rich non-tandem repeat
region, a central large tandem repeat domain containing
16-amino-acid repetitive units, regions rich in potential N-glyco-
sylation sites, two cysteine-rich domains, a putative GDPH
proteolytic cleavage site, three epidermal growth factor (EGF)-like
domains, a hydrophobic transmembrane domain and a short
cytoplasmic tail. The MUC4 mucin is considered to be a
homologue of the rat sialo-mucin complex (SMC, rat MUC4)
because of similarities in their structural organisation (Komatsu
et al, 1999; Moniaux et al, 1999). The SMC is also a heterodimeric
glycoprotein composed of an O-glycosylated mucin subunit ASGP-
1, and an N-glycosylated transmembrane subunit ASGP-2 contain-
ing two EGF domains (Komatsu et al, 2000). The mucin MUC4 also
possesses two subunits: an extracellular mucin-like subunit,
MUC4, and a growth factor-like transmembrane subunit, MUC4b,
containing three EGF-like domains (Moniaux et al, 1999, 2001).
The overexpression of SMC is associated with the suppression of
both cell adhesion and immune killing of tumour cells by altering
cell-surface properties and promoting tumour growth in vitro or
in vivo (Komatsu et al, 1999, 2000). The SMC acts as a ligand for
the receptor tyrosine kinase ErbB2/HER2/neu, via one of its two Received 8 May 2008; revised 16 June 2008; accepted 23 June 2008
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sEGF-like domains, and induces its phosphorylation (Komatsu
et al, 2001; Carraway et al, 2001b, 2002a,b). Similarly, MUC4 has
been shown to be involved in the growth and metastasis of
pancreatic cancer cells (Singh et al, 2004; Moniaux et al, 2007). In
pancreatic cancer cells, MUC4 induces ultra-structural alterations
and promotes tumour cell proliferation and survival and interferes
in the interaction of tumour cells with extracellular matrix
(Chaturvedi et al, 2007; Moniaux et al, 2007).
In this study, we have investigated the functional consequences
of ectopic MUC4 expression in a human ovarian cancer cell line
SKOV3. Our studies demonstrate a direct association of the MUC4
mucin with increased motility in ovarian cancer cells. We also
show that MUC4 interacts with HER2, enhances its expression and
potentiates its downstream signalling.
MATERIALS AND METHODS
Cell culture and stable transfection of MUC4-expression
construct
The MUC4 cDNA is very large (29kb); therefore, it was difficult to
clone the entire coding sequence into any available expression
vector. Thus, we reduced the size of the repetitive sequence (by
decreasing the number of tandem repeats) and generated an
MUC4-expression plasmid, which encodes a protein of 320kDa
(Moniaux et al, 2007). The SKOV3 ovarian cancer cells were
procured from ATCC (Manassas, VA, USA) and cultured in DMEM
medium supplemented with 10% foetal calf serum and antibiotics.
The cultures were maintained in a humidified atmosphere at 371C
with 5% CO2. The MUC4-expression plasmid and empty vector
(pSecTag/MUC4 and pSegTag) were stably transfected in SKOV3
ovarian cancer cells by Fugene (Invitrogen Corp., Carlsbad, CA,
USA), following the manufacturer’s protocol. The Zeocin-resistant
colonies were isolated by the ring cloning method and maintained
in medium supplemented with 250mgml
 1 Zeocin (Invitrogen
Corp.). Medium was replaced with complete medium without
antibiotic supplement at least 5 days before any analysis.
RNA isolation and quantitative RT–PCR for HER2 mRNA
Transcript levels of HER2 in MUC4-transfected SKOV3 cells were
measured by SYBR
s Premix Ex Taqt kit. cDNA was synthesised
using 2mg of total RNA, oligo(dT)18 primer and Superscript RT
(Invitrogen Corp.). Quantitative real-time PCR was performed
using 1ml of a 1:5 dilution of first-strand cDNA using the SYBR
Premix Ex Taq kit (Takara Bio, Madison, WI, USA) and primers
specific to HER2 and RPL13A on an ABI 7500 Sequence Detection
System (Applied Biosystems, Foster, CA, USA). The receptor
tyrosine kinase HER2 was amplified using the forward primer 50-
TCA CCT ACA ACA CAG ACA CGT TTG-30 and the reverse primer
50-ATC CCA CGT CCG TAG AAG GTA-30, whereas RPL13A was
amplified using the forward primer 50-ATC GTG GCT AAA CAG
GTA CTG-30 and the reverse primer 50-GCA CGA CCT TGA GGG
CAG C-30. The efficiency of the PCR and the specificity of primers
were determined using serial dilutions of template cDNA and
dissociation curve analysis. Each cDNA sample was used in
triplicate, and a reaction without any cDNA was used as negative
control. The levels of HER2 mRNA were then normalised to the
RPL13A mRNA levels, and results were graphically represented as a
fold difference in HER2 mRNA level in MUC4-overexpressing
versus empty-vector-transfected cells.
Immunoprecipitation and immunoblot analysis
Cells were grown to 70–80% confluence in a 5% CO2 incubator at
371C. Cells were rinsed once with ice-cold phosphate-buffered
saline (PBS) containing 1mM sodium orthovanadate and lysed in
Triton X-100 lysis buffer (150mM NaCl, 50mM Tris–HCl [pH 8.0],
5m M NaF, 1.0% Triton X-100, 1mM sodium orthovanadate, 5mg
of aprotinin per ml and 5mg of leupeptin per ml) for 25–35min
at 41C. The lysates were centrifuged at 16000g for 20min at
41C. Protein concentrations were measured using the micro-BCA
protein estimation kit (Bio-Rad, Hercules, CA, USA). Equal
amounts of protein were incubated overnight with anti-MUC4
(mouse monoclonal) or anti-HER2 (Rabbit polyclonal) antibodies
in a 500-ml total volume. Protein Aþ G-Sepharose beads
(Oncogene Research, Boston, MA, USA) were added to the
lysate–antibody mix and incubated on a rotating platform for
3h at 41C and washed four times with lysis buffer. The
immunoprecipitates or total cell lysates were electrophoretically
resolved on a gel. Sodium dodecyl sulphate–agarose (2%) gel
electrophoresis was performed for MUC4 using 20mg protein
samples under reducing conditions. For HER2, FAK, Akt, ERK,
p38 (rabbit polyclonal) and b-actin (mouse monoclonal) expres-
sion, SDS–PAGE (10%) was performed under similar conditions.
Resolved proteins were transferred on to the PVDF membrane.
After quick washing in PBST (PBS and 0.1% Tween 20), the
membranes were blocked in 5% non-fat dry milk in PBS for at least
2h and then incubated with primary antibodies (anti-MUC4,
both activated form and total of HER2, FAK, Akt, ERK, p38 and
b-actin). The immunoblots were washed five times (5 10min),
incubated with anti-mouse (for MUC4 and b-actin blots) and anti-
rabbit (for HER2, FAK, Akt, ERK and p38 blots) horseradish
peroxidase-conjugated secondary antibodies, washed five times
(5 10min), reacted with enhanced chemiluminescence ECL
reagent (Amarsham Bioscience, Buckinghamshire, UK) and
exposed to X-ray film to detect the signal.
Confocal immunofluorescence microscopy
Derived cells and SKOV3 were seeded at low density on sterilised
cover slips and allowed to grow for 20h. Cells were washed with
Hanks buffer containing 0.1M HEPES, and fixed in ice-cold
methanol at  201C for 2min and blocked with 10% goat serum
(Jackson Immunoresearch Labs Inc., West Grove, PA, USA)
containing 0.05% Tween-20 for at least 30min. For Phalloidin
staining, cells were fixed in 3.6% formaldehyde–PBS solution and
permeabilised with 0.1% TritonX-100 in PBS for 20min at room
temperature. After the blocking step and a quick wash in PBS,
cells were incubated with the anti-MUC4 monoclonal antibody,
and with anti-HER2 polyclonal antibodies for 60min at room
temperature. Cells were then washed (4 5min) with PBS
containing 0.05% Tween-20 (PBST) and then incubated with
FITC-conjugated anti-mouse and Texas red-conjugated anti-rabbit
secondary antibodies (Jackson Immunoresearch Labs Inc., West
Grove, PA, USA) for 30min at room temperature in the dark. Cells
were washed (5 5min) again and mounted on glass slides in anti-
fade Vectashield mounting medium (Vector Laboratories, Burlin-
game, CA, USA). Laser confocal microscopy was performed by
using an LSM 510 microscope (Carl Zeiss GmbH, Thornwood, NY,
USA). Photographs were taken in each channel separately and
digitally merged for co-localisation studies.
Motility assay
For motility assays, 0.5 10
6 cells were plated in the top chamber
of monocoated polyethylene teraphthalate membranes (six-well
insert, pore size 8mm) (Becton Dickinson, San Jose, CA, USA). The
cells were incubated for 24h, and the cells that did not migrate
through the pores in the membrane were removed by scraping the
membrane with a cotton swab. The migrated cells in the
membrane were stained with a diff-Quick cell stain kit, and cells
in 10 random fields of view at  10 magnification were counted
and expressed as the average number of cells per field of view.
Three independent experiments were performed in each case. The
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experiments with the standard deviation indicated.
RESULTS
Ectopic expression of the MUC4 mucin in transfectants
We have screened a large number of human ovarian cancer cell
lines for expression of MUC4. Our recent study showed that MUC4
is expressed in above 95% of ovarian tumours (Chauhan et al,
2006); however, it was not detected in the majority of cell lines that
were screened (SKOV3, OVCAR3, OVCAR5, OVCAR8, A2780,
COV362.4, COV 664, COV434, KGN, SB247, etc.). To investigate
the function of MUC4, the cDNA of MUC4 was stably expressed in
SKOV3 cells and transfectants were analysed by immunoblotting
(8G7 antibody) and confocal microscopy of the immunostained
cells. Expression of MUC4 was observed in the MUC4-transfected
pooled population of cells (SKOV3-MUC4) and not in the
vector control (SKOV3-Vec) (Figure 1A). CD18/HPAF is a
MUC4-expressing pancreatic cancer cell line used as a positive
control (Figure 1A). Immunofluorescence confocal microscopy
showed the expression and localisation of MUC4 in both the
plasma membrane and cytoplasm in more than 90% of the MUC4-
transfected cells, whereas the vector-transfected control cells
showed no MUC4 staining (Figure 1B). Propedium iodide was
used as a nuclear stain.
MUC4 expression enhances the motility of SKOV3 cells
and causes a rearrangement of the actin cytoskeleton
We analysed the cellular motility in both vector-transfected
and MUC4-overexpressing cells by using Boyden’s chamber assay.
The MUC4-transfected cells showed a significant (Po0.05)
increase in motility when compared with the vector-transfected
cells (Figure 2A). Cell motility is typically associated with the
coordinated disassembly and reformation of the cortical actin
network (Cunningham et al, 1991, 1992). Polymerisation of
globular actin (G-actin) leads to the formation of long fibrous
molecules called filamentous actin (F-actin). The localisation and
distribution of F-actin was analysed by Phalloidin staining in both
MUC4-overexpressing and vector-transfected SKOV3 cells. Con-
focal microscopy of the Phalloidin-stained cells showed filopodia
(white arrow), lammelopodia (green arrow) and microspikes
(yellow arrow) in MUC4-transfected SKOV3 cells (Figure 2B). In
contrast, the vector-transfected SKOV3 cells showed less staining
in the cytoplasm and did not show any cellular outgrowth
(Figure 2B). Presence of structures like lammelopodia, filopodia
and microspikes may be a cause of increased motility in the
MUC4-transfected cells.
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Figure 1 Expression profile of MUC4 in MUC4-transfected SKOV3 cells. (A) Western blot analysis of MUC4 expression in the vector-transfected
(SKOV3-Vec) and MUC4-transfected (SKOV3-MUC4) SKOV3 cell line. The MUC4-expressing pancreatic cancer cell line CD18/HPAF was used as a
positive control. A total of 20mg protein from cell extracts was resolved by electrophoresis on a 2% SDS-agarose gel, transferred to the PVDF membrane
and probed with anti-MUC4 mouse monoclonal antibody (8G7). The membrane was then incubated with horseradish peroxidase-labeled goat anti-mouse
immunoglobulin. The signal was detected using an electrochemiluminescence reagent kit. The MUC4 mucin is a high molecular weight glycoprotein and the
predicted size of the transfected MUC4 protein is 320kDa. (B) Localisation of MUC4 by confocal microscopy. Cells were grown at low density on sterilised
cover slips, washed and fixed in ice-cold methanol at  201C. After blocking with 10% goat serum, cells were incubated with the anti-MUC4 mouse
monoclonal antibody, washed and followed by incubation with FITC-conjugated goat anti-mouse IgG ( 630 original magnification).
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in SKOV3 cells
Our previous studies have shown that the knockdown of MUC4
expression significantly reduces the expression level and phos-
phorylation status of HER2 in the CD18/HPAF pancreatic cell
line (Singh et al, 2004). The overexpression of HER2 has also
been correlated with increased cellular dynamics and motility in
breast cancer cells (Grothey et al, 2000). The expression of
HER2 transcript was measured by quantitative real-time reverse-
transcription assay in MUC4-transfected SKOV3 cells. There was
no significant variation in the HER2 transcript level (P-values
by applying the t-test: 0.889) (Figure 3A). Western blot analysis
of HER2 in MUC4-transfected SKOV3 cells showed an increased
expression of HER2 and its activated form, pY
1248HER2, as
compared with the vector-transfected cells (Figure 3B). Further-
more, our reciprocal co-immunoprecipitation studies indicated
that MUC4 and HER2 interact with each other in the MUC4-
transfected cells (Figure 3C). Confocal microscopy and digital
merging of the MUC4- and HER2-immunostained cells demon-
strated significant colocalisation of both the proteins in the MUC4-
transfected SKOV3 cells (Figure 3D).
Activation of HER2 downstream cell signalling in
MUC4-transfected SKOV3 cells
Downstream signalling of HER2 promotes survival and motility of
cancer cells (Gabarra-Niecko et al, 2003; Mitra and Schlaepfer,
2006). Focal adhesion kinase is linked to the downregulation of
HER2 activity at the cellular periphery, which appears to be
important for the formation of motile cells (Mitra and Schlaepfer,
2006). Focal adhesion kinase is a non-receptor tyrosine
kinase localised to focal adhesions (Schaller et al, 1992). It is
phosphorylated in response to a number of stimuli including the
clustering of integrins (Kornberg et al, 1991). Focal adhesion
kinase is overexpressed in invasive and metastatic tumours
(Owens et al, 1996). An increase level of activated FAK (pY925)
was observed in MUC4-transfected SKOV3 cells when compared
with the vector-transfected cells (Figure 4). The levels of total FAK,
however, remained unchanged in both MUC4- and vector-
transfected cells (Figure 4), suggesting that MUC4 activates FAK,
either by a direct or an indirect mechanism, which may be
responsible to the greater motility observed in the MUC4-
transfected cells.
The effect of MUC4 on signalling through the AKT and ERK and
p38 pathways was also examined in both SKOV3 sublines. The
ERK1/2 and Akt signalling pathways play a major role in the
migration of cancer cells, respectively. The MUC4-transfected
SKOV3 cells showed a significant increase in the levels of activated
ERK1/2 and Akt (Figure 4) compared with the vector-transfected
cells (Figure 4). The total levels of ERK1/2 and Akt, however,
remained unchanged (Figure 4). The increased activation of ERK1/
2 and Akt may be due to the interaction of the ectopically
expressed MUC4 with HER2. The expression level of phospho p38
and total p38 did not show any variation in both the MUC4 and
empty vector-transfected cells (data not shown).
DISCUSSION
The mucin MUC4 is aberrantly expressed in several epithelial
malignancies. Our recent studies revealed an overexpression of
MUC4 in ovarian (Chauhan et al, 2006) and pancreatic tumours
(Andrianifahanana et al, 2001), whereas its expression was
downregulated in prostate cancer (Singh et al, 2006). Other studies
from our lab have shown that MUC4 is involved in pancreatic
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Figure 2 Effect of MUC4 overexpression on the motility and actin organisation of SKOV3 cells. (A) Cells (0.5 10
6) were plated on non-coated
membranes for the cellular motility assays. The cells were incubated for 24h and allowed to move under a chemotactic effect. The cells that did not migrate
through the pores in the membrane were removed by scraping the membrane with a cotton swab, whereas the cells that migrated through the pores were
stained. The number of cells traversing the membrane was determined by averaging ten random fields of view at  10. The data are expressed as the
average number of cells per fields of view and is the average of three independent experiments. Cell motility was significantly (Po0.05) increased in the
MUC4-transfected SKOV3 cells. (B) Cells were seeded on cover slips and fixed with 3.7% formaldehyde and permeabilised with 0.1% Triton X-100. Cells
were stained with 50mgml
 1 fluorescent Phalloidin conjugate solution. SKOV3 cells transfected by MUC4 were associated with the presence of more
microspikes (yellow arrows), lammelopodia (green arrows) and filopodia (white arrows)-like cellular projections with dense actin specifically at the cellular
protrusions compared with the empty vector control cells (original magnification 1000 ).
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et al, 2007). In this study, we have provided experimental evidence
that MUC4 interacts with HER2, potentiates its downstream
signalling and enhances the motility of ovarian cancer cells. Our
findings provide experimental support for the hypothesis that
MUC4 expression is associated with a higher metastatic potential
and thereby a poor prognosis in ovarian cancer.
One of the important observations of this study was the
interaction of MUC4 and HER2 in ovarian cancer cells, which was
also associated with the potentiation of HER2 downstream
signalling. Normally, epithelial cells have polarised morphology
with apical, basal and lateral regions. The mucin MUC4, wherever
present in normal cells, has an apical localisation. However, during
the course of malignant transformation, cells lose their polarity,
which may allow MUC4 to form novel protein–protein interac-
tions (such as between MUC4 and HER2) with proteins that are
normally localised to the basal or lateral surfaces (Ramsauer et al,
2003, 2006). In fact, MUC1, another transmembrane mucin, has
pY1248HER2
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Figure 3 The mucin MUC4 interacts with HER2 and induces the expression of HER2. (A) Estimation of HER2 mRNA levels in MUC4-transfected SKOV3
ovarian cancer cells by real-time RT–PCR. A total of 2mg of RNA was reverse-transcribed and diluted to a total volume of 100ml( 5  dilution). A total of
1ml of this cDNA was used in each reaction in a total reaction volume of 10ml. Each reaction was plated in triplicate. The results are expressed as the fold
changes of HER2 in MUC4-expressed SKOV3 cells relative to that in the vector-transfected cells. No significant change was observed in HER2 transcript
levels compared with empty vector-transfected cells (P-values by applying the t-test: 0.889). (B) Western blot analysis for HER2 expression and HER2
tyrosine phosphorylation in SKOV3-derived cell lines. A total of 20mg of protein from the cell lysate was resolved by SDS–PAGE, transferred to a PVDF
membrane and probed with antibodies against MUC4, HER2, phosphor-Tyr
1248 HER2 and b-actin. SKOV3 cells transfected by MUC4 showed an increased
expression and tyrosine phosphorylation of HER2 at the Tyr
1248 residue. No phosphorylation of HER2 was seen in the SKOV3-vector control. (C)
Reciprocal co-immunoprecipitation analysis to show the interactions between MUC4 and HER2. Lysates from the MUC4-overexpressing SKOV3 cell lines
were utilised for immunoprecipitation with MUC4 and HER2 antibodies. The immunoprecipitates were electrophoretically resolved on 2% SDS-agarose (for
MUC4) and 10% polyacrylamide gel (for HER2), and immunoblotted with anti-MUC4 or anti-HER2 antibodies. The isotype antibodies were used as
immunoprecipitation controls. (D) Co-localisation of MUC4 and HER2 in SKOV3 MUC4-transfected cells. Cells were grown at low density on sterilised
cover slips, washed and fixed in ice-cold methanol at  201C. After blocking with 10% goat serum, cells were incubated with the anti-MUC4 mouse
monoclonal antibody and anti-HER2 polyclonal antibody followed by incubation with FITC-conjugated goat anti-mouse IgG ( 630 original magnification).
The green staining shows MUC4 expression, red staining shows HER2 expression and the yellow staining shows the co-localisation.
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sbeen shown to interact with growth factor receptors – such as the
ErbB family members, which are otherwise restricted to the lateral
and basal cell borders (Schroeder et al, 2001; Scibetta et al, 2001;
Canbay, 2003). Moreover, the rat homologue of MUC4 (rMUC4/
SMC) was also shown to interact with ErbB2/neu in multiple cell
types (Carraway and Idris, 2001a; Carraway et al, 2001b, 2002a,b).
Therefore, our observations on MUC4–HER2 interaction in
SKOV3 have a strong functional relevance in ovarian cancer
progression. What yet remains to be investigated is the structural
basis of this interaction. On the basis of previous findings with
rat MUC4, we may speculate a direct interaction of MUC4 with
HER2, involving one of the three EGF domains present in the
transmembrane (MUC4-b) subunit of MUC4. It is also likely that
the cytoplasmic tail of MUC4 or the glycans present on MUC4 may
indirectly interact with HER2, as has been shown recently for
MUC1-EGFR (Ramasamy et al, 2007). The observation that HER2
expression is increased in MUC4-transfected SKOV3 cells is
consistent with our previous finding where we observed a
correlative decrease in HER2 expression in antisense-RNA-
induced stable MUC4-knockdown cells (Singh et al, 2004).
Altogether, our present data and previous observations clearly
indicate a role of MUC4 in the regulation of HER2 expression
(Singh et al, 2004; Chaturvedi et al, 2007). Notably, our
observations are not consistent with previous findings, where rat
SMC, although forming a complex with ErbB2 and inducing its
phosphorylation, did not affect ErbB2 expression (Carraway et al,
2001b, 2002a,b; Singh et al, 2004). Interestingly, no significant
changes in the expression of HER2 transcript were observed in
MUC4-transfected SKOV3 cells, suggesting that MUC4-mediated
HER2 regulation may occur by post-transcriptional mechanism(s).
This is consistent with a recently published report by us in
pancreatic cancer cells (Chaturvedi et al, 2008). In a recent study,
MUC1 has been shown to inhibit the degradation of ErbB1/HER1
by regulating the receptor trafficking (Pochampalli et al, 2007) and
possibly, a similar mechanism may also exist for MUC4-mediated
HER2 regulation, which needs to be investigated.
Another important finding of this study was the enhanced cell
motility in the MUC4-transfected SKOV3 cells as compared with the
vector-transfected controls (Figure 2A). This was also consistent
with our previous results, where we observed a three-fold decrease
in cell motility upon silencing of MUC4 expression (Singh et al,
2004). Although the exact molecular mechanism for MUC4-
associated change in cell motility is yet to be deciphered, we predict
an important role for augmented HER2 downstream signalling in
this process. Exogenous overexpression of HER2 and its activation
has been correlated with increased invasiveness and cellular motility
(Grothey et al, 2000). Studies on rat MUC4 (SMC) have also
demonstrated that MUC4-induced HER2/neu activation may be
important in tumour growth and metastasis in rat mammary
carcinoma cells (Komatsu et al, 2001; Carraway et al, 2002a). Results
from this study have shown an increased activation of FAK in
MUC4-transfected SKOV3 cells, whereas the total FAK remained
unchanged. Similarly, we also observed an activation of Akt.
Previous studies support our observations that HER2 downstream
signalling leads to FAK, Akt and ERK activation and is implicated in
cell survival and motility (Gabarra-Niecko et al, 2003; Mitra and
Schlaepfer, 2006). Recent studies demonstrate that FAK is linked to
the downregulation of HER2 activity at the cell periphery, which
appears to be important for the formation of motile cells (Mitra and
Schlaepfer, 2006). Therefore, the activation of FAK may be related to
the increased motility of MUC4-transfected SKOV3 cells. Cell
movement is typically associated with a coordinated assembly
and disassembly of the cortical actin network (Cunningham et al,
1991, 1992). For migration, a cell requires the formation of cell
membrane protrusions containing actin filaments and a continuous
process of actin polymerisation near the leading edges (Feldner
and Brandt, 2002). It has been shown that the cytoplasmic tail of
MUC1 may affect actin polymerisation and increase motility in
cancer cells (Parry et al, 1990). In line with this, our data also shows
that the actin cytoskeleton is predominantly localised at the leading
edges and cellular projections of MUC4-overexpressing SKOV3
cells.
In conclusion, this work is the first report of the direct
association of MUC4 with the motile phenotype in ovarian cancer
cells. The ectopic expression of MUC4 alters HER2 expression at
protein levels, thus potentiate its activation of downstream
signalling. Overall, our results demonstrate that MUC4 plays a
crucial role in regulating the motility of ovarian cancer cells
possibly by altering the expression and activation of HER2 and its
downstream signalling.
p-ERK1/2
ERK1/2
S
K
O
V
3
-
V
e
c
S
K
O
V
3
-
M
U
C
4
MUC4 
p-Akt
Akt
pFAK
FAK
-actin
Figure 4 The mucin MUC4 induces HER2 downstream cell signalling in
SKOV3 cells. A total of 20mg of cell lysates from SKOV3-vector and
SKOV3-MUC4-transfected cells were used for immunoblotting with
MUC4, FAK, phosphorylated FAK, ERK, phosphorylated ERK, Akt and
phosphorylated Akt antibodies. For MUC4 detection, proteins were
resolved on 2% SDS-agarose gel; other proteins were resolved on 10%
SDS-polyacrylamide gel. b-actin was used as an internal control. SKOV3
cells transfected by MUC4 clearly showed increased activation of FAK, Akt
and ERK in MUC4-transfected SKOV3 cells, whereas the vector-transfected
cells showed a lesser activation of FAK, Akt and ERK. The levels of total
FAK, Akt and ERK remain unchanged.
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